Johnson & Johnson (NYSE:JNJ) Shares Sold by Oregon Public Employees Retirement Fund

Oregon Public Employees Retirement Fund lessened its stake in Johnson & Johnson (NYSE:JNJGet Rating) by 4.7% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 696,152 shares of the company’s stock after selling 34,091 shares during the quarter. Johnson & Johnson comprises about 1.6% of Oregon Public Employees Retirement Fund’s holdings, making the stock its 4th largest holding. Oregon Public Employees Retirement Fund’s holdings in Johnson & Johnson were worth $113,723,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Waterfront Wealth Inc. boosted its holdings in Johnson & Johnson by 4.5% in the 3rd quarter. Waterfront Wealth Inc. now owns 3,653 shares of the company’s stock worth $632,000 after acquiring an additional 157 shares during the period. Tobam boosted its stake in shares of Johnson & Johnson by 284.4% during the 3rd quarter. Tobam now owns 72,528 shares of the company’s stock valued at $11,848,000 after buying an additional 53,659 shares during the last quarter. Hudock Inc. boosted its stake in shares of Johnson & Johnson by 8.6% during the 3rd quarter. Hudock Inc. now owns 7,840 shares of the company’s stock valued at $1,280,000 after buying an additional 621 shares during the last quarter. Lee Financial Co boosted its stake in shares of Johnson & Johnson by 8.3% during the 3rd quarter. Lee Financial Co now owns 2,765 shares of the company’s stock valued at $451,000 after buying an additional 211 shares during the last quarter. Finally, Crossmark Global Holdings Inc. boosted its stake in shares of Johnson & Johnson by 3.9% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 50,207 shares of the company’s stock valued at $8,202,000 after buying an additional 1,867 shares during the last quarter. Hedge funds and other institutional investors own 67.94% of the company’s stock.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $168.31 on Wednesday. Johnson & Johnson has a 1-year low of $155.72 and a 1-year high of $186.69. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.43 and a quick ratio of 1.18. The business’s fifty day moving average price is $175.98 and its two-hundred day moving average price is $171.06. The firm has a market capitalization of $440.04 billion, a PE ratio of 23.44, a P/E/G ratio of 3.21 and a beta of 0.56.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 EPS for the quarter, beating analysts’ consensus estimates of $2.23 by $0.12. The company had revenue of $23.71 billion for the quarter, compared to analyst estimates of $23.90 billion. Johnson & Johnson had a return on equity of 35.37% and a net margin of 19.95%. The company’s quarterly revenue was down 4.4% compared to the same quarter last year. During the same period last year, the company earned $2.13 earnings per share. On average, research analysts expect that Johnson & Johnson will post 10.04 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st will be issued a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.69%. The ex-dividend date of this dividend is Friday, February 17th. Johnson & Johnson’s dividend payout ratio (DPR) is 62.95%.

Insider Activity

In related news, VP Thibaut Mongon sold 35,246 shares of the firm’s stock in a transaction dated Friday, November 4th. The stock was sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following the completion of the transaction, the vice president now owns 40,133 shares of the company’s stock, valued at $6,869,966.94. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In related news, VP Thibaut Mongon sold 35,246 shares of the firm’s stock in a transaction dated Friday, November 4th. The stock was sold at an average price of $171.18, for a total transaction of $6,033,410.28. Following the completion of the transaction, the vice president now owns 40,133 shares of the company’s stock, valued at $6,869,966.94. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Joseph J. Wolk sold 14,781 shares of the firm’s stock in a transaction dated Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total value of $2,654,667.60. Following the transaction, the chief financial officer now directly owns 35,812 shares of the company’s stock, valued at approximately $6,431,835.20. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 233,611 shares of company stock valued at $40,960,735. Company insiders own 0.35% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Barclays assumed coverage on Johnson & Johnson in a research note on Monday, October 17th. They set an “equal weight” rating and a $175.00 target price for the company. Atlantic Securities dropped their price target on Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating on the stock in a research report on Wednesday, October 19th. Credit Suisse Group started coverage on Johnson & Johnson in a research report on Thursday, November 17th. They set a “neutral” rating and a $170.00 price target on the stock. Morgan Stanley dropped their price target on Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating on the stock in a research report on Tuesday, December 6th. Finally, Citigroup upped their price target on Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a research report on Monday, December 12th. Seven analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $181.75.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Further Reading

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.